Abstract
While pulmonary ILC2s represent one of the major tissue-resident innate lymphoid cell populations at steady state and are key drivers of cytokine secretion in their occupational niche, their role in pulmonary cancer progression remains unclear. As the programmed cell death protein-1 (PD-1) plays a major role in cancer immunotherapy and immunoregulatory properties, here we investigate the specific effect of PD-1 inhibition on ILC2s during pulmonary B16 melanoma cancer metastasis. We demonstrate that PD-1 inhibition on ILC2s suppresses B16 tumor growth. Further, PD-1 inhibition upregulates pulmonary ILC2-derived TNF-α production, a cytotoxic cytokine that directly induces cell death in B16 cells, independent of adaptive immunity. Together, these results highlight the importance of ILC2s and their anti-tumor role in pulmonary B16 cancer progression during PD-1 inhibitory immunotherapy.
Highlights
Melanoma is a highly aggressive form of cancer that spreads from primary skin sites to various organs throughout the human body [1, 2]
We first assessed the effect of B16 melanoma tumors on ILC2 programmed death-1 receptor (PD-1) expression
The percentage of PD-1+ ILC2s significantly increased after B16 inoculation, from a mean of 15% PD-1+ ILC2s to 60% PD-1+ ILC2s, demonstrating B16 melanoma induces PD-1 expression on pulmonary ILC2s and may subsequently alter anti-tumor effector function (Figure 1D)
Summary
Melanoma is a highly aggressive form of cancer that spreads from primary skin sites to various organs throughout the human body [1, 2]. While effective treatment is attainable if diagnosed at the early stages, 20% of melanomas diagnosed in advanced stages resist treatment [3, 4]. Pulmonary metastasis is the most common progression in the late stages of cancer diagnosis [5]. According to the World Health Organization, over 106,000 melanomas were diagnosed, and 7,000 new fatalities occurred in the United States in 2020. While the rates of melanoma diagnosis continue to be alarming, molecularly targeted approaches, including inhibition of immune checkpoints such as programmed death-1 receptor (PD-1) have significantly improved patient outcomes over the last decade. A Food and Drug Administration-approved antibody directed at PD-1 inhibition enhanced median overall
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.